Cancers

Overview

Cancers are diseases in which cells acquire heritable changes that release them from the controls on proliferation, survival and position. They are distinguished from benign neoplasms not by growth alone but by invasion through basement membrane and the capacity to metastasize, and they are classified by tissue of origin — carcinomas from epithelium, sarcomas from mesenchyme, leukemias and lymphomas from haematopoietic lineages — because origin predicts behavior and treatment better than site alone. The shared features across that diversity are few and well described: sustained proliferative signaling, evasion of growth suppressors and of cell death, replicative immortality, angiogenesis, invasion and metastasis, altered metabolism, and escape from immune destruction.

A cancer arises by clonal evolution. Somatic mutations accumulate over a lifetime, and the small subset that fall in driver genes — oncogenes activated by mutation or amplification, tumor suppressors lost — confer a proliferative advantage that selection amplifies, while the far larger number of passenger mutations carry no advantage but complicate interpretation. Because the process is evolutionary, a tumor is not genetically uniform: subclones diverge, and treatment selects among them, which is the general reason resistance emerges rather than a peculiarity of any one drug. Most deaths follow from metastasis rather than the primary tumor, and the disease's tissue context — stroma, vasculature and infiltrating immune cells — determines much of how it grows and responds.

Diagnosis integrates clinical assessment, imaging, laboratory markers and histopathology, with molecular profiling now determining treatment in many tumor types, and staging describing anatomic extent to guide intent. Treatment combines local modalities, surgery and radiotherapy, with systemic ones: cytotoxic chemotherapy directed at proliferating cells, targeted agents directed at a specific driver, endocrine therapy where growth is hormone-dependent, and immunotherapy that restores an immune response rather than attacking the tumor directly. Incidence, mortality and survival are the measures used to track this burden across populations, and they vary widely by geography and access, since much of the difference in outcome between settings reflects stage at diagnosis rather than the biology of the disease.

Recent Publications Summary

Recent publications examined cancers across a range of clinical contexts, from palliative care and patient experience to diagnostic prediction, imaging, and treatment-related safety. In a longitudinal study of 134 newly admitted cancer patients receiving palliative care in Ho Chi Minh City, Vietnam, mean health outcome scores measured with the African Palliative Care Association Integrated Palliative Outcome Scale improved over time, with a significant monthly reduction of 4.6 points, indicating better health outcomes during the first year after admission 42469974Jul. In Switzerland, a multicentre cross-sectional survey of 4,408 adults with non-sex-specific cancers assessed gender-related differences in patient-reported experiences across the cancer care pathway, including pretreatment, treatment, and post-treatment phases 42442810Jul. In Soweto, South Africa, qualitative interviews with 13 Traditional Health Practitioners found that some had encountered clients with cancer-related symptoms and often referred patients to biomedical facilities when symptoms were serious or unclear, highlighting their perceived role in community awareness and early detection 42439203Jul.

Other studies focused on improving cancer diagnosis and treatment monitoring. A multidisciplinary retrospective study of pancreaticobiliary lesions evaluated integrated clinical, radiological, laboratory, and pathological predictors to better distinguish malignant from non-malignant disease, reflecting the challenge of identifying aggressive cancers among a broad lesion spectrum 42340777Jun. In boron neutron capture therapy, a simulation study investigated neural network-based Compton event filtering to improve 478 keV prompt gamma-ray imaging under high-background conditions, with the filtered event retention rate showing a strong linear relationship with tumor 10B concentration, supporting quantitative imaging capability during cancer treatment 42208575May. Another study explored associations between radioactive iodine treatment for hyperthyroidism and subsequent cancer incidence and mortality, including overall and site-specific cancers, addressing long-term safety concerns of this therapy 41700975Feb.

Theranostic and platform-level advances also linked emerging technologies to cancer care. A study of a stable NIR-II emissive radical system for immunogenic sono/photodynamic theranostics reported bright NIR-II emission, photothermal conversion, and efficient type-I reactive oxygen species generation after 808 nm irradiation, with in vivo near-complete tumor ablation under photoactivation and additional ultrasound-responsive activity 42265059Jun. Separately, a review on mRNA COVID-19 vaccines noted that the mRNA platforms developed for vaccination have opened new possibilities for treating cancers and other diseases, underscoring broader translational potential beyond infectious disease prevention 41850696Mar.

What Changes, What Holds

1. Cancer care now appears to improve measurable patient outcomes over time in palliative settings
NEW DIRECTION Longitudinal outcome tracking suggests that cancers are not only a diagnostic and prognostic problem but also a condition whose symptom burden and reported health status can change meaningfully after admission to palliative care 42469974Jul. The gender-experience survey and traditional-practitioner interviews add a care-pathway and community-awareness dimension, but they do not alter the baseline account of cancers as malignant disease requiring integrated assessment 42442810Jul42439203Jul.

2. Cancer evaluation is moving toward integrated prediction and treatment-linked imaging, while long-term safety questions remain open
METHOD These studies mainly refine how cancers and cancer-related lesions are assessed: combining clinical, radiological, laboratory, and pathological signals to improve discrimination, and using neural-network filtering to strengthen quantitative gamma imaging during therapy 42340777Jun42208575May. The radioactive iodine analysis adds a separate safety-monitoring question about later cancer risk after treatment, but it does not change the baseline understanding of cancers as entities identified through integrated diagnostic workup 41700975Feb.

3. Cancer therapy is expanding into theranostic and platform-based strategies beyond conventional diagnosis and monitoring
NEW DIRECTION Stable NIR-II emissive radical systems and mRNA vaccine platforms point to cancers as targets for emerging treatment technologies that combine imaging, phototherapy, immune activation, and broader translational reuse of vaccine engineering 42265059Jun41850696Mar. That extends the baseline’s diagnostic framing by adding therapeutic platform development, but it does not displace the established view that cancers are defined and tracked through clinical, imaging, laboratory, and histopathological assessment.

Overview update candidates: palliative-care outcome trajectories in cancer; integrated multimodal prediction/imaging methods; and emerging theranostic or platform-based treatment approaches.